Saroglitazar is a novel, first-in-class, dual peroxisome proliferator-activated receptor (PPAR) agonist with predominant PPAR-α and moderate PPAR-γ activity. It is the first approved drug in the 'Glitazar' class in India, developed specifically for the management of diabetic dyslipidemia and hypertriglyceridemia in patients with type 2 diabetes mellitus not controlled by statin therapy. It addresses the dual pathology of insulin resistance and atherogenic dyslipidemia common in the Indian phenotype.
Adult: 4 mg once daily, before the first meal of the day (usually breakfast).
Note: Administer orally with or without food, but preferably before the first meal. Tablet should be swallowed whole with a glass of water. Do not crush or chew. Dose timing should be consistent each day.
Saroglitazar acts as a dual agonist for the nuclear transcription factors Peroxisome Proliferator-Activated Receptor alpha (PPAR-α) and gamma (PPAR-γ). Its action is biased, with a PPAR-α/γ agonistic ratio of approximately 3:1. Activation of PPAR-α upregulates genes involved in fatty acid β-oxidation, leading to reduced plasma triglyceride levels. Activation of PPAR-γ enhances insulin sensitivity in adipose tissue, muscle, and liver, improving glycemic control.
Pregnancy: Category NA (Not Assigned). Animal studies have shown fetal toxicity. Contraindicated in pregnancy. Women of childbearing potential should use effective contraception.
Driving: Generally safe. However, patients should be cautioned about potential side effects like dizziness, vertigo, or hypoglycemia which may impair the ability to drive or operate machinery.
| Gemfibrozil (strong CYP2C8 inhibitor) | Markedly increases Saroglitazar plasma concentration. Risk of toxicity. | Major - Contraindicated |
| Cyclosporine (CYP3A4/2C8 inhibitor) | Increases Saroglitazar exposure. Dose monitoring required. | Moderate |
| Rifampicin (strong CYP inducer) | Decreases Saroglitazar plasma concentration, reducing efficacy. | Moderate |
| Repaglinide (CYP2C8 substrate) | Potential for altered repaglinide levels. Monitor blood glucose. | Moderate |
| Atorvastatin/other Statins | Increased risk of myalgia, myositis, or rhabdomyolysis. Monitor for muscle pain. | Moderate |
| Sulfonylureas/Insulin | Increased risk of hypoglycemia. May require dose reduction of the anti-diabetic agent. | Moderate |
| Warfarin | Potential interaction via protein binding displacement. Monitor INR closely. | Moderate |